uniQure (NASDAQ:QURE) Stock Price Up 7.2% – Here’s Why

uniQure N.V. (NASDAQ:QURE)’s share price rose 7.2% during trading on Wednesday . The company traded as high as $28.72 and last traded at $28.69. Approximately 716,792 shares traded hands during trading, a decline of 73% from the average daily volume of 2,658,588 shares. The stock had previously closed at $26.76.

Wall Street Analyst Weigh In

QURE has been the subject of a number of research analyst reports. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and lifted their price target for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Wolfe Research began coverage on shares of uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $35.00 price objective on shares of uniQure in a research report on Monday, March 2nd. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.83.

uniQure Trading Up 4.2%

The company has a market cap of $1.76 billion, a P/E ratio of -8.01 and a beta of 0.98. The business has a fifty day moving average price of $20.44 and a 200-day moving average price of $21.87. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, analysts forecast that uniQure N.V. will post -3.68 earnings per share for the current year.

Insider Activity

In other news, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the sale, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

Institutional investors have recently made changes to their positions in the stock. Torren Management LLC bought a new stake in shares of uniQure in the fourth quarter valued at approximately $28,000. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc bought a new stake in uniQure during the fourth quarter worth about $48,000. Smartleaf Asset Management LLC bought a new stake in uniQure during the fourth quarter worth about $48,000. Finally, CIBC Private Wealth Group LLC bought a new stake in uniQure during the third quarter worth about $50,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.